MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
Hosted on MSN1d
BTIG Downgrades Inari Medical (NARI)
Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.
Fintel on MSN1d
BTIG Downgrades Palo Alto Networks (PANW)
Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to ...
BTIG Sticks to Their Buy Rating for Globus Medical (GMED)
In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...
Why Palo Alto Networks Stock Dropped on Wednesday
Palo Alto Networks (NASDAQ: PANW) investors just cannot catch a break. Over the past three days, this cybersecurity stock has ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend Winners
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they could rally this year.
Here are some of BTIG's top picks for the first half of 2025
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...